this is a discussion room not an agreement room.
clinical stats is one thing, but the overall context is another.
you have missed in all this fine tuning and slicing and dicing, the key elements to this
The reality is there is NO threat to patient safety, none!
With 80% mortality add those together and MSB has already proven the therapy.
MORE FINE TUNING WHILE MORE aGVHD patients DIE? THIS is your idea of expertise and fairness???
the FDA has as well. Perhaps legal action will concentrate their minds?
as it did with the BLA
The comments in here defy logic and reason, you are really excelling tonight/sorry this morning. Sure you're on Australian time?.
CEO Itescu needs to go, page-150
-
- There are more pages in this discussion • 764 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.45 |
Change
0.065(4.69%) |
Mkt cap ! $1.655B | |||
| Open | High | Low | Value | Volume |
| $1.39 | $1.50 | $1.38 | $7.016M | 4.856M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 10425 | $1.44 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.45 | 44243 | 5 |
View Market Depth
| Last trade - 16.10pm 11/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |